PD153035 (Synonyms: SU-5271; AG1517; ZM 252868)

Name: PD153035
Brand: MedChemExpress
SKU: HY-14346
Rating: 5.0 (8 reviews)

Cat. No.: HY-14346 Purity: 98.83%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

For research use only. We do not sell to patients.

PD153035 Chemical Structure

CAS No. : 153436-54-5

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 73	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 73	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 66	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 86	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 328	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of PD153035:

PD153035 Hydrochloride In-stock

8 Publications Citing Use of MCE PD153035

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

IC₅₀ & Target^[1]

EGFR

6 pM (Ki)

EGFR

25 pM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.025 nM Compound: 14	Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells	[PMID: 9154973]
A-431	IC₅₀	0.025 nM Compound: 32	Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles	[PMID: 8568816]
A-431	IC₅₀	0.029 nM Compound: 3	Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells. Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.	[PMID: 7658435]
A-431	IC₅₀	0.2 μM Compound: 21, PD153035	Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA	[PMID: 23434139]
A-431	IC₅₀	0.2 μM Compound: 49, PD-153035	Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA	[PMID: 20403700]
A-431	IC₅₀	0.2 μM Compound: 20, PD-153035	Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA	[PMID: 22370340]
A-431	IC₅₀	0.2 μM Compound: 17, PD-153035	Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA	[PMID: 19748785]
A-431	IC₅₀	0.23 μM Compound: 20, PD-153035	Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA	[PMID: 22204741]
A-431	IC₅₀	0.23 μM Compound: 18, PD-153035	Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
A-431	IC₅₀	0.23 μM Compound: 25, PD153035	Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
A-431	IC₅₀	0.23 μM Compound: 13, PD-153035	Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA	[PMID: 20092323]
A-431	IC₅₀	12.6 μM Compound: 25, PD153035	Cytotoxicity against human A431 cells overexpressing EGFR assessed as inhibition of cell proliferation treated for 12 hrs measured after 36 hrs by CYQUANT dye based assay Cytotoxicity against human A431 cells overexpressing EGFR assessed as inhibition of cell proliferation treated for 12 hrs measured after 36 hrs by CYQUANT dye based assay	[PMID: 23375090]
A-431	IC₅₀	12.6 μM Compound: 20, PD-153035	Cytotoxicity against human A431 cells overexpressing EGFR incubated for 12 hrs measured after 36 hrs by CYQUANT assay Cytotoxicity against human A431 cells overexpressing EGFR incubated for 12 hrs measured after 36 hrs by CYQUANT assay	[PMID: 22370340]
A-431	IC₅₀	12.6 μM Compound: 17, PD-153035	Cytotoxicity against human A431 cells after 48 hrs by CYQUANT cell proliferation assay Cytotoxicity against human A431 cells after 48 hrs by CYQUANT cell proliferation assay	[PMID: 19748785]
A-431	IC₅₀	2.26 μg/mL Compound: PD-153035	Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
A-431	IC₅₀	26.29 μM Compound: 1, PD-153035	Reversibility of antiproliferative activity against human A431 cells after recovery for 68 hrs by MTT assay Reversibility of antiproliferative activity against human A431 cells after recovery for 68 hrs by MTT assay	[PMID: 17154492]
A-431	IC₅₀	4.4 μM Compound: PD153035	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 23900004]
A-431	IC₅₀	4.4 μM Compound: PD-153035	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 20095624]
A-431	IC₅₀	8.31 μM Compound: 1, PD-153035	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 17154492]
A549	IC₅₀	8.13 μg/mL Compound: PD-153035	Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
B16-F10	IC₅₀	1.74 μg/mL Compound: PD-153035	Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
Bcap37	IC₅₀	13.7 μM Compound: PD-153035	Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay	[PMID: 17681471]
Bcap37	IC₅₀	15.7 μM Compound: PD153035	Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23811258]
Bcap37	IC₅₀	15.7 μM Compound: PD153035	Antiproliferative activity against human Bcap37 cells by MTT assay Antiproliferative activity against human Bcap37 cells by MTT assay	[PMID: 24583357]
Bcap37	IC₅₀	8.9 μM Compound: PD-153035	Antitumor activity against human Bcap37 cells by MTT method Antitumor activity against human Bcap37 cells by MTT method	[PMID: 17317179]
BGC-823	IC₅₀	14.4 μM Compound: PD153035	Growth inhibition of human BGC823 cells after 72 hrs by MTT assay Growth inhibition of human BGC823 cells after 72 hrs by MTT assay	[PMID: 23811258]
BGC-823	IC₅₀	14.4 μM Compound: PD153035	Antiproliferative activity against human BGC823 cells by MTT assay Antiproliferative activity against human BGC823 cells by MTT assay	[PMID: 24583357]
BGC-823	IC₅₀	16.8 μM Compound: PD-153035	Growth inhibition of human BGC823 cells after 72 hrs by MTT assay Growth inhibition of human BGC823 cells after 72 hrs by MTT assay	[PMID: 17681471]
BGC-823	IC₅₀	6.9 μM Compound: PD-153035	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 20817326]
BGC-823	IC₅₀	6.9 μM Compound: PD-153035	Antitumor activity against human BGC823 cells by MTT method Antitumor activity against human BGC823 cells by MTT method	[PMID: 17317179]
EA.hy 926	IC₅₀	7.1 μM Compound: 3a, PD-153035	Antiproliferative activity against human EAhy926 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human EAhy926 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
HEK293	IC₅₀	260 nM Compound: 13; CA336	Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay	[PMID: 30973735]
HeLa	IC₅₀	> 10 μM Compound: PD153035	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23900004]
HT-29	IC₅₀	> 10 μM Compound: PD153035	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23900004]
HT-29	IC₅₀	10.1 μM Compound: 3a, PD-153035	Antiproliferative activity against human HT-29 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
HT-29	IC₅₀	10.1 μM Compound: 1a, PD-153035	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 21033670]
HUVEC	IC₅₀	4.06 μM Compound: PD153035	Antiproliferative activity against HUVEC after 72 hrs by MTT assay Antiproliferative activity against HUVEC after 72 hrs by MTT assay	[PMID: 23900004]
MCF7	IC₅₀	3.21 μg/mL Compound: PD-153035	Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
MCF7	IC₅₀	4.7 μM Compound: 3a, PD-153035	Antiproliferative activity against human MCF7 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
MCF7	IC₅₀	4.7 μM Compound: 1a, PD-153035	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 21033670]
MDA-MB-468	IC₅₀	0.68 μM Compound: 16; PD153036	Inhibition of EGFR in human MDA-MB-468 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method Inhibition of EGFR in human MDA-MB-468 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method	[PMID: 30878832]
MDCK-II	IC₅₀	1.73 μM Compound: 43, PD153035	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay	[PMID: 24184213]
MDCK-II	IC₅₀	2.32 μM Compound: 43, PD153035	Inhibition of human BCRP expressed in MDCK2 cells assessed as pheophorbide A accumulation treated 30 mins before pheophorbide A addition measured up to 120 mins by flow cytometry Inhibition of human BCRP expressed in MDCK2 cells assessed as pheophorbide A accumulation treated 30 mins before pheophorbide A addition measured up to 120 mins by flow cytometry	[PMID: 24184213]
NIH3T3	IC₅₀	> 10 μM Compound: PD153035	Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 23900004]
NIH3T3	IC₅₀	> 10 μM Compound: PD-153035	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 20095624]
PC-3	IC₅₀	> 10 μM Compound: 1a, PD-153035	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 21033670]
PC-3	IC₅₀	13.7 μM Compound: PD-153035	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20817326]
PC-3	IC₅₀	13.7 μM Compound: PD-153035	Antitumor activity against human PC3 cells by MTT method Antitumor activity against human PC3 cells by MTT method	[PMID: 17317179]
PC-3	IC₅₀	8.3 μM Compound: PD153035	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 23811258]
PC-3	IC₅₀	8.3 μM Compound: PD153035	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 24583357]
PC-3	IC₅₀	8.9 μM Compound: PD-153035	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 17681471]

In Vitro

PD153035 (SU 5271) inhibits EGF-stimulated receptor autophosphorylation in A431 human epidermoid carcinoma cells, with an IC₅₀ of 14 nM^[1]. PD153035 (SU 5271) has little effect on PDGFR, FGFR, CSF-1 receptor, the insulin receptor, or on src tyrosine kinases at concentrations as high as 50 μM. PD153035 (SU 5271) rapidly suppresses autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocks EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation^[2]. PD153035 (SU 5271) causes a dose-dependent growth inhibition of EGF receptor-positive cell lines, beginning at less than micromolar concentrations, and the IC₅₀ is less than 1 pM in most cases^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PD153035 (SU 5271) levels in the plasma and tumor rise to 50 and 22 μM within 15 minutes following a single i.p. dose of 80 mg/kg. While the plasma levels of PD153035 (SU 5271) falls below 1 μM by 3 hours, in the tumors it remains at micromolar concentrations for at least 12 hours. The tyrosine phosphorylation of the EGF receptor is rapidly suppressed by 80-90% in the tumors^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

360.21

Formula

C₁₆H₁₄BrN₃O₂

CAS No.

153436-54-5

Appearance

Solid

Color

White to off-white

SMILES

COC1=C(C=C(C2=C1)N=CN=C2NC3=CC(Br)=CC=C3)OC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (92.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7762 mL	13.8808 mL	27.7616 mL
5 mM	0.5552 mL	2.7762 mL	5.5523 mL
10 mM	0.2776 mL	1.3881 mL	2.7762 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.83%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (260 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. [Content Brief]

[2]. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. [Content Brief]

[3]. Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [Content Brief]

[4]. Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. [Content Brief]

Cell Assay ^[3]	Different EGF receptor-overexpressing cell lines (A43 1, Difi, MDA-MB-468, MDA-MB-231, DU145, SiHa, C4i, and MEl 80) are treated with PD153035 at increasing concentrations of 0.125-2.5 p.M. Growth inhibitory effect in monolayer cell culture is assessed^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice: Mice are injected with PD153035 (SU 5271) (80 mg/kg) or vehicle and rumors are excised at 20 minutes and 180 minutes and extracts are prepared. Two mice are used for each time point and the experiment is repeated four times. Within each of the four experiments ANOVA is used to compare the inhibition by PD153035 (SU 5271) of the EGF-stimulation^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. [Content Brief] [2]. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. [Content Brief] [3]. Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [Content Brief] [4]. Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7762 mL	13.8808 mL	27.7616 mL	69.4040 mL
	5 mM	0.5552 mL	2.7762 mL	5.5523 mL	13.8808 mL
	10 mM	0.2776 mL	1.3881 mL	2.7762 mL	6.9404 mL
	15 mM	0.1851 mL	0.9254 mL	1.8508 mL	4.6269 mL
	20 mM	0.1388 mL	0.6940 mL	1.3881 mL	3.4702 mL
	25 mM	0.1110 mL	0.5552 mL	1.1105 mL	2.7762 mL
	30 mM	0.0925 mL	0.4627 mL	0.9254 mL	2.3135 mL
	40 mM	0.0694 mL	0.3470 mL	0.6940 mL	1.7351 mL
	50 mM	0.0555 mL	0.2776 mL	0.5552 mL	1.3881 mL
	60 mM	0.0463 mL	0.2313 mL	0.4627 mL	1.1567 mL
	80 mM	0.0347 mL	0.1735 mL	0.3470 mL	0.8675 mL

PD153035 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

PD153035 (Synonyms: SU-5271; AG1517; ZM 252868)

Customer Review

Other Forms of PD153035:

8 Publications Citing Use of MCE PD153035

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

PD153035 Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

PD153035 (Synonyms: SU-5271; AG1517; ZM 252868)

Customer Review

Other Forms of PD153035:

PD153035 Related Antibodies

8 Publications Citing Use of MCE PD153035

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

PD153035 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

PD153035 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report